Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Medtronic plc has entered another important phase of portfolio expansion after announcing plans to acquire privately held SPR Therapeutics for about $650 million in cash, strengthening its position in chronic pain management.</li><li>The deal would give Medtronic access to SPR’s SPRINT Peripheral Nerve Stimulation system, a 60-day therapy designed to deliver pain relief without a permanent implant.</li><li>The announcement follows a stronger operating backdrop for Medtronic, which reported 6% organic revenue growth in fiscal Q3 2026, its highest growth rate in 10 quarters, supported by momentum in cardiac ablation, diabetes, neuromodulation, and several new platform launches.</li></ul>

Medtronic plc has entered another important phase of portfolio expansion after announcing plans to acquire privately held SPR Therapeutics for about $650 million in cash, strengthening its position in chronic pain management.The deal would give Medtronic access to SPR’s SPRINT Peripheral Nerve Stimulation system, a 60-day therapy designed to deliver pain relief without a permanent implant.The announcement follows a stronger operating backdrop for Medtronic, which reported 6% organic revenue growth in fiscal Q3 2026, its highest growth rate in 10 quarters, supported by momentum in cardiac ablation, diabetes, neuromodulation, and several new platform launches.

Medtronic Buyout Move: The $650 Million Pain Therapy Play Explained!

Medtronic Plc

Medtronic Buyout Move: The $650 Million Pain Therapy Play Explained!